[Mefloquine chemoprophylaxis of malaria in the Brazilian Amazonia].
In a randomised double-blind study 122 volunteers living in an endemic malarious area in Amazonian Rondônia state were divided into 4 groups to study malaria suppression. . The first group received 500 mg of mefloquine every month, group II 250 mg every two weeks, group III a tablet of Fansidar (500 mg sulphadoxine + 25mg pyrimethamine) a week and group IV placebo. Acute attacks of malaria occurred in one individual in group I, 2 subject in group II, and 6 individuals in groups III and IV. Protection with mefloquine was significant compared with the placebo group. Both treatment regimens with mefloquine were effective suppressants in an area of high prevalence of drug multiresistant Plasmodium falciparum transmission.
Santos
J B
JB
Núcleo de Medicina Tropical e Nutrição, Universidade de Brasília, DF.
Prata
A
A
Wanssa
E
E
D000293:Adolescent; D000328:Adult; D001938:Brazil; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D016778:Malaria, Falciparum / Q000517:prevention & control*; D016780:Malaria, Vivax / Q000517:prevention & control*; D008297:Male; D015767:Mefloquine / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D013997:Time Factors
D015767:Mefloquine
Quimioprofilaxia da malária com mefloquina na Amazônia Brasileira.